Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-Current Deffered Revenue (2020 - 2025)

Tango Therapeutics has reported Non-Current Deffered Revenue over the past 6 years, most recently at $30.4 million for Q2 2025.

  • Quarterly results put Non-Current Deffered Revenue at $30.4 million for Q2 2025, down 44.09% from a year ago — trailing twelve months through Jun 2025 was $30.4 million (down 44.09% YoY), and the annual figure for FY2024 was $44.8 million, down 32.87%.
  • Non-Current Deffered Revenue for Q2 2025 was $30.4 million at Tango Therapeutics, down from $37.5 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for TNGX hit a ceiling of $116.6 million in Q3 2021 and a floor of $5.8 million in Q1 2021.
  • Median Non-Current Deffered Revenue over the past 5 years was $68.7 million (2023), compared with a mean of $68.3 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 1898.7% in 2021 and later plummeted 44.09% in 2025.
  • Tango Therapeutics' Non-Current Deffered Revenue stood at $114.7 million in 2021, then dropped by 19.73% to $92.1 million in 2022, then fell by 27.59% to $66.7 million in 2023, then crashed by 32.87% to $44.8 million in 2024, then plummeted by 32.01% to $30.4 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $30.4 million (Q2 2025), $37.5 million (Q1 2025), and $44.8 million (Q4 2024) per Business Quant data.